← Back to contracts

Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Research Coordinating Center

US · IL National Institutes of Health (NIH) grant unknown #RFA-DK-27-136

Summary

The National Institutes of Health (NIH) is soliciting applications for a Research Coordinating Center focused on optimal treatment strategies for the use of Anti-Obesity Medications (AOMs) in children and adolescents. The coordinating center will likely oversee, support, and integrate research activities across multiple study sites investigating AOM use in pediatric populations. This is a forecasted federal grant/cooperative agreement opportunity posted via Grants.gov under RFA-DK-27-136, indicating it is anticipated but not yet fully open for applications.

What they want

Establishment and operation of a Research Coordinating Center (RCC) to support optimal treatment strategies for the use of Anti-Obesity Medications (AOMs) in children and adolescents. The RCC is expected to coordinate multi-site research activities under NIH funding mechanism RFA-DK-27-136, issued by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) implied by the 'DK' designator.

How they evaluate

Submission: Grants.gov federal grants portal

Risks & flags

  • Opportunity is in 'forecasted' status only — full solicitation details, budget, and eligibility criteria are not yet available, limiting competitive preparation time.
  • No response deadline, award value, or scope details disclosed at this stage, making it difficult to assess competitiveness or wiring.

Market context

inferred from NAICS
R&D in Physical, Engineering, Life Sciences (except Nanotech & Biotech)
NAICS 541715
US market size
$95B
Typical award
$100K – $50M+
Typical buyers
DoDNSFNIHNASADOE
Commonly required
DCAA-compliant accountingITARCMMC L2
Optimal Treatment Strategies for use of An…
$unknown
Onboard